Veterinary Medicines Information website

Vectormune FP ILT + AE (--) Lyophilisate and solvent for suspension for injection

Authorised
  • Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live
  • Avian encephalomyelitis virus, strain Calnek 1143, Live
Download as PDF

Product identification

Medicine name:
Vectormune FP ILT + AE (--) Lyophilisate and solvent for suspension for injection
Active substance:
  • Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live
  • Avian encephalomyelitis virus, strain Calnek 1143, Live
Target species:
  • Chicken
Route of administration:
  • Wing-web-stab use

Product details

Active substance and strength:
  • Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live
    Presentation_strength:2.7 to 4.5 log₁₀ TCID₅₀ Reference:HSE Index:0
  • Avian encephalomyelitis virus, strain Calnek 1143, Live
    Presentation_strength:2.7 to 4.5 log₁₀ EID₅₀ Reference:HSE Index:1
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Wing-web-stab use
    • Chicken
      • Not applicable
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Available in:
  • Austria
  • Belgium
  • Bulgaria
  • Cyprus
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Latvia
  • Luxembourg
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
Package description:
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials; solvent: 5 vials; 5 pronged applicators, Content:Lyophilisate: 2000 doses; solvent: 20 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial; solvent: 1 vial; 1 pronged applicator, Content:Lyophilisate: 1000 doses; solvent: 10 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials; solvent: 5 vials; 5 pronged applicators, Content:Lyophilisate: 1000 doses; solvent: 10 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 10 vials; solvent: 10 vials; 10 pronged applicators, Content:Lyophilisate: 1000 doses; solvent: 10 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 10 vials; solvent: 10 vials; 10 pronged applicators, Content:Lyophilisate: 2000 doses; solvent: 20 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial; solvent: 1 vial; 1 pronged applicator, Content:Lyophilisate: 2000 doses; solvent: 20 ml

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ceva-Phylaxia Zrt.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva-Phylaxia Zrt.
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change: